A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors

doi:10.1038/s41467-018-03915-4

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
	Wang, Tingting 1,2,3; Wang, Dangge 1,2,3; Yu, Haijun1,2 ; Feng, Bing 1,2,3; Zhou, Fangyuan 1,2; Zhang, Hanwu 1,2; Zhou, Lei 1,2; Jiao, Shi 4; Li, Yaping1,2
刊名	NATURE COMMUNICATIONS
	2018-04-18
卷号	9
ISSN号	2041-1723
DOI	10.1038/s41467-018-03915-4
文献子类	Article
英文摘要	Vaccines to induce effective and sustained antitumor immunity have great potential for postoperative cancer therapy. However, a robust cancer vaccine simultaneously eliciting tumor-specific immunity and abolishing immune resistance continues to be a challenge. Here we present a personalized cancer vaccine (PVAX) for postsurgical immunotherapy. PVAX is developed by encapsulating JQ1 (a BRD4 inhibitor) and indocyanine green (ICG) co-loaded tumor cells with a hydrogel matrix. Activation of PVAX by 808 nm NIR laser irradiation significantly inhibits the tumor relapse by promoting the maturation of dendritic cells and eliciting tumor infiltration of cytotoxic T lymphocytes. A mechanical study reveals that NIR light-triggered antigen release and JQ1-mediated PD-L1 checkpoint blockade cumulatively contribute to the satisfied therapeutic effect. Furthermore, PVAX prepared from the autologous tumor cells induces patient-specific memory immune response to prevent tumor recurrence and metastasis. The PVAX model might provide novel insights for postoperative immunotherapy.
资助项目	National Natural Science Foundation of China[31671024] ; National Natural Science Foundation of China[31622025] ; National Natural Science Foundation of China[81521005] ; National Natural Science Foundation of China[81690265]
WOS关键词	T-CELLS ; PHOTOTHERMAL THERAPY ; MELANOMA PATIENTS ; IMMUNE-RESPONSES ; NANOPARTICLES ; BLOCKADE ; COMBINATION ; NEOANTIGENS ; ANTIGENS ; IMPROVE
WOS研究方向	Science & Technology - Other Topics
语种	英语
出版者	NATURE PUBLISHING GROUP
WOS记录号	WOS:000430286800007
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279800]
专题	药物制剂研究中心中科院受体结构与功能重点实验室新药研究国家重点实验室
通讯作者	Yu, Haijun; Li, Yaping
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China; 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China; 4.Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China
推荐引用方式 GB/T 7714	Wang, Tingting,Wang, Dangge,Yu, Haijun,et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors[J]. NATURE COMMUNICATIONS,2018,9.
APA	Wang, Tingting.,Wang, Dangge.,Yu, Haijun.,Feng, Bing.,Zhou, Fangyuan.,...&Li, Yaping.(2018).A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.NATURE COMMUNICATIONS,9.
MLA	Wang, Tingting,et al."A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors".NATURE COMMUNICATIONS 9(2018).